生物技术公司Replimune Group Inc.预计将宣布与美国食品药品监督管理局（FDA）达成一项协议，为其晚期黑色素瘤治疗药物重新提交上市申请。
根据报道，双方已就相关事宜进行了沟通，并有望在近期正式公布这一安排。此举旨在解决此前申请过程中可能存在的问题，并为该疗法的最终获批铺平道路。
Replimune的这款疗法针对晚期黑色素瘤患者，属于其研发管线中的重要候选药物。与监管机构达成协议，通常意味着公司获得了明确的路径指引，以补充数据或调整方案，从而再次寻求监管批准。这一进展对于依赖该产品未来商业前景的Replimune而言，是一个积极的信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.